Publication
Preclinical molecular imaging to study the biodistribution of antibody derivatives in oncology
Warnders, J. F., 2018, [Groningen]: Rijksuniversiteit Groningen. 191 p.Research output: Thesis › Thesis fully internal (DIV)

Documents
- Title and contents
Final publisher's version, 112 KB, PDF document
- Chapter 1
Final publisher's version, 763 KB, PDF document
- Chapter 2
Final publisher's version, 1.37 MB, PDF document
- Chapter 3
Final publisher's version, 1.99 MB, PDF document
- Chapter 4
Final publisher's version, 1.58 MB, PDF document
- Chapter 5
Final publisher's version, 4.03 MB, PDF document
- Chapter 6
Final publisher's version, 4.63 MB, PDF document
- Chapter 7
Final publisher's version, 336 KB, PDF document
- Chapter 8
Final publisher's version, 348 KB, PDF document
- Chapter 9
Final publisher's version, 335 KB, PDF document
- Dankwoord
Final publisher's version, 73.2 KB, PDF document
- About the author
Final publisher's version, 64.8 KB, PDF document
- Complete thesis
Final publisher's version, 13.1 MB, PDF document
- Propositions
Final publisher's version, 47.6 KB, PDF document
Given the overexpression on a variety of tumor cells, EpCAM, CEA and HER3 are interesting targets for BiTEs and nanobodies. In order to facilitate their drug development, an anti-EpCAM BiTE, anti-CEA BiTE and anti-HER3 nanobody construct have been radiolabeled with 89Zr. 89Zr-PET was used to study their organ distribution and tumor uptake. Radiolabeling of the anti-CEA BiTE was additionally used to study its in vivo integrity in serum and tumors. The obtained preclinical data have been used to setup a clinical trial, in which 89Zr-PET is used to study organ distribution and tumor uptake of this anti-CEA BiTE in cancer patients.
This thesis also describes the selection and preclinical evaluation of anti-HER2 nanobodies, fluorescently labeled with IRDye 800CW. Shortly after injection, the best performing nanobody enabled tumor visualization of HER2-positive tumors using optical imaging. It accumulated quicker in these tumors than 800CW-trastuzumab, a fluorescently labeled anti-HER2 drug.
Translated title of the contribution | Preklinische moleculaire beeldvorming om de biodistributie te bestuderen van antilichaam derivaten binnen de oncologie |
---|---|
Original language | English |
Qualification | Doctor of Philosophy |
Awarding Institution | |
Supervisors/Advisors |
|
Award date | 4-Jul-2018 |
Place of Publication | [Groningen] |
Publisher | |
Publication status | Published - 2018 |
Download statistics
ID: 61780808